It was first officially authorized by the Food and Drug Administration (FDA) in 2018, and the treatment received full regulatory approval for patients with deleterious or potentially deleterious germline BRCA-mutated (gBRCAm) and human epidermal growth factor receptor 2-negative (HER2-negative) disseminated breast cancer who received chemotherapy before surgery (neoadjuvant), after surgery (adjuvant), or in a metastatic disease context. Here, ERBB2 is linked to metastatic neoplasm.